bpc-157 fda warning Understanding the Legal Risks of and Other Unapproved Peptides – Holt Law FDA's Overreach on Compounded Peptides
Description
Clinical trial safety data: In the Phase 2 trial, adverse events were comparable to placebo
After treatment initiation and dose increases, patients should be observed carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting)
Once the solution runs clear, community sources describe refrigerating the vial immediately
Water dynamics in the hydration shells of biomolecules
